Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
James M. Frates currently holds 177,104 shares of Amylyx Pharmaceuticals, Inc. (AMLX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, James M. Frates has been a net seller of AMLX stock. They have purchased $290.9K and sold $44.4M worth of shares.
James M. Frates's most recent insider trade was on Jan 6, 2026, when they sold 3,326 shares at $11.11 per share.
James M. Frates serves as Executive at Amylyx Pharmaceuticals, Inc. (AMLX). They have executed 483 insider transactions totaling $44.7M over their tenure at the company.
James M. Frates holds the position of Executive at Amylyx Pharmaceuticals, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 20 years and currently hold a stake valued at $0.
James M. Frates has shown a selling trading pattern, with $290.9K in total purchases and $44.4M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by James M. Frates was on May 6, 2019, when they sold $1.3M worth of SAGE shares. This transaction involved 8,000 shares at $162.22 per share.
James M. Frates currently owns 177,104 shares of Amylyx Pharmaceuticals, Inc. (AMLX), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of James M. Frates's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. James M. Frates has 483 Form 4 filings on record as an insider at Amylyx Pharmaceuticals, Inc..
Set alerts for James M. Frates and 40,000+ other insiders.